mesalamine has been researched along with Disease Models, Animal in 107 studies
Mesalamine: An anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHASALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed)
mesalamine : A monohydroxybenzoic acid that is salicylic acid substituted by an amino group at the 5-position.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pulmonary fibrosis is one of the most important pathological processes associated with paraquat (PQ) poisoning." | 8.12 | 5‑Aminosalicylic acid attenuates paraquat‑induced lung fibroblast activation and pulmonary fibrosis of rats. ( Chen, H; Cui, J; Gong, Y; Liu, L; Ma, Y; Tian, Y; Tong, F; Wang, J; Wang, Y; Zhang, X, 2022) |
| "We examined whether metoclopramide (MCP), a modulator of dopamine and serotonin receptors, alleviated colitis and had synergistic effects when coadministered with 5-aminosalicylic acid (5-ASA) in an experimental model of colitis." | 7.91 | A colon-specific prodrug of metoclopramide ameliorates colitis in an experimental rat model. ( Jeong, S; Jung, Y; Kim, D; Kim, W; Yang, Y; Yoo, JW, 2019) |
| "The present study developed novel zinc ion cross-linked alginate/N-succinyl-chitosan (NSC) blend microspheres (MS) for co-delivery of zinc and 5-aminosalicylic acid (5-ASA) for synergistic therapy of colitis." | 7.85 | Co-delivery of zinc and 5-aminosalicylic acid from alginate/N-succinyl-chitosan blend microspheres for synergistic therapy of colitis. ( Bai, X; Duan, H; Gao, C; Liu, M; Liu, Z; Lü, S; Qin, H; Wei, Y; Wu, X; Zhang, X, 2017) |
| "Male mice imprinting control regions (ICR) were randomly divided into five groups: normal, TNBS-induced colitis, colitis treated with liquiritigenin at low dose (10 mg/kg) and high dose (20 mg/kg), or mesalazine (10 mg/kg)." | 7.81 | Amelioration of trinitrobenzene sulfonic acid-induced colitis in mice by liquiritigenin. ( Bae, H; Cha, JM; Jang, SE; Kim, DH; Kim, HJ; Lee, CH; Lim, SJ; Min, JK; Park, JW, 2015) |
| "An experimental ulcerative colitis model was established by rectal injection of oxazolone into the colon of 40 Wistar rats randomly divided into four groups." | 7.75 | Therapeutic effects of Clostridium butyricum on experimental colitis induced by oxazolone in rats. ( Cui, YL; Ding, TT; Yang, X; Zhang, HQ; Zhang, HX; Zhang, JJ; Zhao, JS, 2009) |
| "Previous experiments in rats with chemically induced colitis have shown that the antioxidant N-acetylcysteine plus mesalamine (5-ASA) exerted a significantly greater therapeutic effect in promoting mucosal healing when compared to either agent alone." | 7.74 | Luminal antioxidants enhance the effects of mesalamine in the treatment of chemically induced colitis in rats. ( Ancha, HR; Harty, RF; Kurella, RR; Lightfoot, S; McKimmey, CC, 2008) |
| "Irrespective of the treatment regiment, ATB-429 was more effective than mesalamine in reducing the severity of colitis." | 7.74 | Enhanced activity of a hydrogen sulphide-releasing derivative of mesalamine (ATB-429) in a mouse model of colitis. ( Caliendo, G; Cirino, G; Distrutti, E; Fiorucci, S; Mencarelli, A; Orlandi, S; Santagada, V; Santucci, L; Wallace, JL, 2007) |
| "The aims of this study were to examine the ability of the antioxidant N-acetylcysteine (NAC) and mesalamine (5-ASA) alone and in combination to affect TNBS-induced colitis in rat." | 7.73 | Antioxidant therapy with N-acetylcysteine plus mesalamine accelerates mucosal healing in a rodent model of colitis. ( Ancha, H; Harty, RF; Lightfoot, S; Siddiqui, A; Stewart, CA; Tedesco, D, 2006) |
| "Colitis was induced using the iodoacetamide rat model, and rats were divided into different dietary groups of 6 rats each: 1, normal chow diet (control); 2, diet supplemented with iron; 3, iron supplementation and lycopene; 4, iron and Beta-carotene; 5, 5-ASA; 6, 5-ASA and lycopene; 7, 5-ASA and iron; 8, 5-ASA, iron, and lycopene." | 7.72 | 5-ASA and lycopene decrease the oxidative stress and inflammation induced by iron in rats with colitis. ( Bujanover, Y; Matas, Z; Nissenkorn, A; Reifen, R, 2004) |
| "The effect of epidermal growth factor on the rate of healing was examined in a rat model of colitis." | 7.68 | Effect of epidermal growth factor on experimental colitis in the rat. ( Bass, P; Luck, MS, 1993) |
| "Colitis was induced in mice by intracolonic (i." | 5.51 | Evaluation of the effect of liposomes loaded with chlorogenic acid in treatment of 2,4,6-trinitrobenzenesulfonic acid-induced murine colitis. ( Chen, C; Czapor-Irzabek, H; Fichna, J; Gorniak, A; Karolewicz, B; Krajewska, JB; Owczarek, A; Pietruszka, P; Tomczyk, D, 2019) |
| "Colitis was induced in female swiss mice by adding DSS 3% to the drinking water." | 5.48 | Antioxidant and anti-inflammatory effect of plumieride in dextran sulfate sodium-induced colitis in mice. ( Andrade, SF; Boeing, T; Bonomini, TJ; da Silva, LM; de Souza, P; Lucinda, RM; Malheiros, A; Mariano, LNB; Somensi, LB, 2018) |
| "A pharmacokinetic model of colon-specific drug delivery developed in a previous study has been validated by use of 5-aminosalicylic acid (5-ASA) as a model anti-inflammatory drug." | 5.30 | Validation of a pharmacokinetic model of colon-specific drug delivery and the therapeutic effects of chitosan capsules containing 5-aminosalicylic acid on 2,4,6-trinitrobenzenesulphonic acid-induced colitis in rats. ( Fujita, T; Muranishi, S; Odoriba, T; Okabe, S; Terabe, A; Tozaki, H; Yamamoto, A, 1999) |
| "Pulmonary fibrosis is one of the most important pathological processes associated with paraquat (PQ) poisoning." | 4.12 | 5‑Aminosalicylic acid attenuates paraquat‑induced lung fibroblast activation and pulmonary fibrosis of rats. ( Chen, H; Cui, J; Gong, Y; Liu, L; Ma, Y; Tian, Y; Tong, F; Wang, J; Wang, Y; Zhang, X, 2022) |
| "We examined whether metoclopramide (MCP), a modulator of dopamine and serotonin receptors, alleviated colitis and had synergistic effects when coadministered with 5-aminosalicylic acid (5-ASA) in an experimental model of colitis." | 3.91 | A colon-specific prodrug of metoclopramide ameliorates colitis in an experimental rat model. ( Jeong, S; Jung, Y; Kim, D; Kim, W; Yang, Y; Yoo, JW, 2019) |
| " The agents tested were: alpha-lactoalbumin (ALAC), a whey protein rich in tryptophan, effective in some animal models of epilepsy and on colon/intestine inflammation, valproic acid (VPA), an effective antiepileptic drug in this seizure model, mesalazine (MSZ) an effective aminosalicylate anti-inflammatory treatment against ulcerative colitis and sodium butyrate (NaB), a short chain fatty acid (SCFA) normally produced in the intestine by gut microbiota, important in maintaining gut health and reducing gut inflammation and oxidative stress." | 3.91 | Intestinal inflammation increases convulsant activity and reduces antiepileptic drug efficacy in a mouse model of epilepsy. ( Avagliano, C; Calignano, A; Citraro, R; Constanti, A; De Caro, C; De Sarro, G; di Cesare Mannelli, L; Ghelardini, C; Leo, A; Mainardi, P; Nesci, V; Russo, E; Striano, P, 2019) |
| " Our aim was to examine local and remote consequences of ASA-Tris administration in 2-,4-,6-trinitrobenzene-sulfonic acid (TNBS)-induced colitis as compared to ASA or mesalamine (5-aminosalicylate) treatment." | 3.88 | Acetylsalicylic acid-tris-hydroxymethyl-aminomethane reduces colon mucosal damage without causing gastric side effects in a rat model of colitis. ( Boros, M; Érces, D; Ghyczy, M; Hartmann, P; Jász, DK; Lajkó, N; Molnár, R; Szűcs, S; Tóth, G; Ugocsai, M; Varga, G, 2018) |
| "The present study developed novel zinc ion cross-linked alginate/N-succinyl-chitosan (NSC) blend microspheres (MS) for co-delivery of zinc and 5-aminosalicylic acid (5-ASA) for synergistic therapy of colitis." | 3.85 | Co-delivery of zinc and 5-aminosalicylic acid from alginate/N-succinyl-chitosan blend microspheres for synergistic therapy of colitis. ( Bai, X; Duan, H; Gao, C; Liu, M; Liu, Z; Lü, S; Qin, H; Wei, Y; Wu, X; Zhang, X, 2017) |
| " The strong inhibitory activity of compound 55 against an in vivo colitis model was confirmed by its dose-dependent inhibitory activity in a rat model of 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced colitis, demonstrating compound 55 as a new potential candidate for the development of therapeutics against IBD." | 3.85 | Discovery and structure-activity relationship studies of 2-benzylidene-2,3-dihydro-1H-inden-1-one and benzofuran-3(2H)-one derivatives as a novel class of potential therapeutics for inflammatory bowel disease. ( Banskota, S; Bist, G; Gurung, P; Kadayat, TM; Kim, JA; Lee, ES; Shrestha, A; Thapa Magar, TB, 2017) |
| " Colonic specificity of 5-ASA tablets (prepared using guar gum and pectin as polymers) was evaluated in vitro using simulated fluids mimicking in vivo environment as well as in vivo method using chemically (2,4,6-trinitrobenzenesulfonic acid and acetic acid)-induced colitis rat model." | 3.81 | In Vivo Evaluation of 5-ASA Colon-Specific Tablets Using Experimental-Induced Colitis Rat Animal Model. ( Bajaj, AN; Deshpande, SG; Nikam, VS; Sawarkar, SP, 2015) |
| "To investigate the therapeutic and immunoregulatory effects of 1,25-dihydroxyvitamin D (1,25(OH)D3) on 2,4,6-trinitrobenzenesulfonic acid (TNBS) -induced colitis in rats." | 3.81 | 1,25-hydroxyvitamin D relieves colitis in rats via down-regulation of toll-like receptor 9 expression. ( Dai, ZH; Lv, H; Qian, JM; Tan, B; Wang, O; Yang, H, 2015) |
| "Male mice imprinting control regions (ICR) were randomly divided into five groups: normal, TNBS-induced colitis, colitis treated with liquiritigenin at low dose (10 mg/kg) and high dose (20 mg/kg), or mesalazine (10 mg/kg)." | 3.81 | Amelioration of trinitrobenzene sulfonic acid-induced colitis in mice by liquiritigenin. ( Bae, H; Cha, JM; Jang, SE; Kim, DH; Kim, HJ; Lee, CH; Lim, SJ; Min, JK; Park, JW, 2015) |
| " Subsequently, its protective effect in indomethacin and iodoacetamide induced colitis in rats (45, 90, 180, 270 mg/kg) and acetic acid induced colitis in mice (65, 130, 250, 500 mg/kg) was assessed." | 3.77 | Protective effect of aqueous extract of Bombax malabaricum DC on experimental models of inflammatory bowel disease in rats and mice. ( Jagtap, AG; Niphadkar, PV; Phadke, AS, 2011) |
| "An experimental ulcerative colitis model was established by rectal injection of oxazolone into the colon of 40 Wistar rats randomly divided into four groups." | 3.75 | Therapeutic effects of Clostridium butyricum on experimental colitis induced by oxazolone in rats. ( Cui, YL; Ding, TT; Yang, X; Zhang, HQ; Zhang, HX; Zhang, JJ; Zhao, JS, 2009) |
| "Previous experiments in rats with chemically induced colitis have shown that the antioxidant N-acetylcysteine plus mesalamine (5-ASA) exerted a significantly greater therapeutic effect in promoting mucosal healing when compared to either agent alone." | 3.74 | Luminal antioxidants enhance the effects of mesalamine in the treatment of chemically induced colitis in rats. ( Ancha, HR; Harty, RF; Kurella, RR; Lightfoot, S; McKimmey, CC, 2008) |
| " In this study, we examined the effects of 2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucoside (THSG), an active component extracted from Polygonum multiflorum Thunb, on acetic acid-induced acute colitis and mitomycin C-induced chronic colitis." | 3.74 | Protective effects of 2,3,5,4'-tetrahydroxystilbene-2-O-beta-d-glucoside, an active component of Polygonum multiflorum Thunb, on experimental colitis in mice. ( Chen, S; Han, T; Wang, J; Wang, X; Zhao, L, 2008) |
| "Irrespective of the treatment regiment, ATB-429 was more effective than mesalamine in reducing the severity of colitis." | 3.74 | Enhanced activity of a hydrogen sulphide-releasing derivative of mesalamine (ATB-429) in a mouse model of colitis. ( Caliendo, G; Cirino, G; Distrutti, E; Fiorucci, S; Mencarelli, A; Orlandi, S; Santagada, V; Santucci, L; Wallace, JL, 2007) |
| "The aims of this study were to examine the ability of the antioxidant N-acetylcysteine (NAC) and mesalamine (5-ASA) alone and in combination to affect TNBS-induced colitis in rat." | 3.73 | Antioxidant therapy with N-acetylcysteine plus mesalamine accelerates mucosal healing in a rodent model of colitis. ( Ancha, H; Harty, RF; Lightfoot, S; Siddiqui, A; Stewart, CA; Tedesco, D, 2006) |
| "Mesalazine, betamethasone, and misoprostol are the best topical agents for radiation proctitis and formalin has an inflammatory effect and should not be used." | 3.73 | Histopathological comparison of topical therapy modalities for acute radiation proctitis in an experimental rat model. ( Aksoy, M; Asoglu, O; Bilge, H; Kapran, Y; Kiremit-Korkut, N; Korkut, C; Parlak, M, 2006) |
| " Clinically, pro-drugs such as olsalazine have been associated with dose-dependent diarrhea, which was likely secondary to ileal secretion induced by the azo linkages, in 17% of patients." | 3.73 | Comparative analysis of the in vitro prosecretory effects of balsalazide, sulfasalazine, olsalazine, and mesalamine in rabbit distal ileum. ( Chang, EB; Hanauer, SB; Kles, KA; Musch, MW; Turner, JR; Vavricka, SR, 2005) |
| "Colitis was induced using the iodoacetamide rat model, and rats were divided into different dietary groups of 6 rats each: 1, normal chow diet (control); 2, diet supplemented with iron; 3, iron supplementation and lycopene; 4, iron and Beta-carotene; 5, 5-ASA; 6, 5-ASA and lycopene; 7, 5-ASA and iron; 8, 5-ASA, iron, and lycopene." | 3.72 | 5-ASA and lycopene decrease the oxidative stress and inflammation induced by iron in rats with colitis. ( Bujanover, Y; Matas, Z; Nissenkorn, A; Reifen, R, 2004) |
| "Effects of an NO-releasing derivative of mesalamine (NCX-456; NO-mesalamine) were compared with those of mesalamine itself and 2 other NO donors in a rat model of colitis." | 3.70 | Enhanced anti-inflammatory effects of a nitric oxide-releasing derivative of mesalamine in rats. ( Asfaha, S; Chapman, K; Del Soldato, P; Fiorucci, S; McKnight, W; Morelli, A; Muscará, MN; Vergnolle, N; Wallace, JL, 1999) |
| "The similarity of the chemiluminescence responses of colonic biopsy specimens from acetic acid induced colitis and ulcerative colitis to a range of conventional antioxidants and standard treatments suggests that this model is a useful method for testing the antioxidant potential of new therapies for inflammatory bowel disease." | 3.69 | Evaluating the antioxidant potential of new treatments for inflammatory bowel disease using a rat model of colitis. ( Blades, S; Blake, DR; Chander, CL; Claxson, AW; Coumbe, A; Millar, AD; Morris, CJ; Panetta, J; Rampton, DS, 1996) |
| "The effect of epidermal growth factor on the rate of healing was examined in a rat model of colitis." | 3.68 | Effect of epidermal growth factor on experimental colitis in the rat. ( Bass, P; Luck, MS, 1993) |
| "Individuals with ulcerative colitis face an increased risk of developing colorectal cancer and would benefit from early chemopreventive intervention." | 2.49 | Differential response of flat and polypoid colitis-associated colorectal neoplasias to chemopreventive agents and heterocyclic amines. ( Chang, WC; Clapper, ML; Cooper, HS; Zenser, TV, 2013) |
| "According to the current paradigm both ulcerative colitis (UC) and Crohn's disease (CD) result from a complex interplay of genetic susceptibility factors, environmental factors, alterations of the physiological intestinal flora and a defective regulation of the intestinal immune system." | 2.42 | Current concept of pathophysiological understanding and natural course of ulcerative colitis. ( Galle, PR; Holtmann, MH, 2004) |
| "Because intestinal inflammation affects the gut microbiota and 5-ASA can change the severity of inflammation, assessing the impact of inflammation and 5-ASA on the gut microbiota is not feasible in a clinical study of patients with UC." | 1.91 | 5-Aminosalicylic acid alters the gut microbiota and altered microbiota transmitted vertically to offspring have protective effects against colitis. ( Akimoto, Y; Hibi, N; Hibi, T; Hisamatsu, T; Kobayashi, T; Kuronuma, S; Lee, STM; Matsuura, M; Miyoshi, J; Nishinarita, Y; Oguri, N; Takeuchi, O; Wada, H, 2023) |
| "However, the PPS-treated colitis group showed higher gene expression of IL-35 EBI3 subunit by 1." | 1.72 | Pentosan Polysulfate Sodium augments the therapeutic effect of 5-Aminosalicylic Acid in DSS colitis model; the role of IL-35 expression. ( AbdElfattah, AA; Ashour, RH; El-Kady, RA; Elmasry, A; Hazem, NM, 2022) |
| "Ulcerative colitis is an inflammatory bowel disease that forms ulcerations in the mucous membrane of the colon and rectum, in which gut microbiota plays a pivotal role in its pathogenesis." | 1.72 | Therapeutic Potential of Metabolites from ( Aljofan, M; Babenko, D; Chulenbayeva, L; Gulyayev, A; Kozhakhmetov, S; Kozhakhmetova, S; Kushugulova, A; Muhanbetganov, N; Nurgaziyev, M; Nurgozhina, A; Sergazy, S; Tuyakova, A, 2022) |
| "Colitis was induced in mice using 2,4,6-trinitrobenzene-sulfonic acid (TNBS), and mice were subsequently treated with either a PD-1 inhibitor or 5-amino-salicylic acid (ASA) as a positive control." | 1.62 | Inhibition of PD-1 Protects against TNBS-Induced Colitis via Alteration of Enteric Microbiota. ( Du, YL; He, J; Huang, HL; Li, YF; Nie, YQ; Xu, HM; Xu, J; Zhao, C; Zhou, YJ; Zhou, YL, 2021) |
| "Skin fibrosis is a complex biological remodeling process occurring in disease like systemic sclerosis, morphea, or eosinophilic fasciitis." | 1.62 | Systemic mesalazine treatment prevents spontaneous skin fibrosis in PLK2-deficient mice. ( Günther, C; Hoffmann, M; Kant, TA; Klapproth, E; Künzel, K; Künzel, SR; Newe, M; Rausch, JSE; Winter, L, 2021) |
| "Colitis was induced in mice by intracolonic (i." | 1.51 | Evaluation of the effect of liposomes loaded with chlorogenic acid in treatment of 2,4,6-trinitrobenzenesulfonic acid-induced murine colitis. ( Chen, C; Czapor-Irzabek, H; Fichna, J; Gorniak, A; Karolewicz, B; Krajewska, JB; Owczarek, A; Pietruszka, P; Tomczyk, D, 2019) |
| "Colitis was induced in female swiss mice by adding DSS 3% to the drinking water." | 1.48 | Antioxidant and anti-inflammatory effect of plumieride in dextran sulfate sodium-induced colitis in mice. ( Andrade, SF; Boeing, T; Bonomini, TJ; da Silva, LM; de Souza, P; Lucinda, RM; Malheiros, A; Mariano, LNB; Somensi, LB, 2018) |
| " DAI and colonic histopathology scores in the normal dosage, high dosage and the 5‑ASA‑SiO2 NP groups demonstrated a significant improvement when compared with the model group." | 1.46 | 5-ASA-loaded SiO2 nanoparticles-a novel drug delivery system targeting therapy on ulcerative colitis in mice. ( Mao, J; Tan, X; Tang, H; Wang, F; Wang, Y; Xiang, D, 2017) |
| "Acetic acid ulcerative colitis (UC) is an experimental condition created due to intra-rectal administration of acetic acid which causes inflammation and ulceration in the lining of colon and rectum." | 1.42 | Mesalazine-probiotics beads for acetic acid experimental colitis: formulation and characterization of a promising new therapeutic strategy for ulcerative colitis. ( Bansal, D; Dubey, N; Ganeshpurkar, A; Pandey, V; Vishwakarma, N, 2015) |
| "Lynch syndrome is caused by germline mutations in DNA mismatch repair genes leading to microsatellite instability (MSI) and colorectal cancer." | 1.42 | Mesalazine and thymoquinone attenuate intestinal tumour development in Msh2(loxP/loxP) Villin-Cre mice. ( Campregher, C; Edelmann, W; Evstatiev, R; Gasche, C; Khare, V; Kortüm, B; Kucherlapati, MH; Lang, M; Mittlböck, M; Pinter, M; Scharl, T; Schmid, G, 2015) |
| "Treatment of mesalazine, an anti-ulcerative colitis drug, down-regulated Foxp3 and IL-17 expression in BTLA positive T cells along with attenuated severity for colitis." | 1.42 | BTLA associates with increased Foxp3 expression in CD4(+) T cells in dextran sulfate sodium-induced colitis. ( Fu, XX; Kong, B; Wang, CY; Wang, WD; Xiang, WY; Xu, JF; Zeng, JC; Zhang, HX; Zhang, JA; Zheng, XB; Zhong, J; Zhu, B, 2015) |
| "The rat model of ulcerative colitis was used to evaluate the efficiency of our loaded pellets as a drug carrier." | 1.40 | Preparation and evaluation of colon adhesive pellets of 5-aminosalicylic acid. ( Elamin, ES; Ping, Q; Qiao, H; Sun, M; Xu, M, 2014) |
| "Disease progression was monitored daily by observation of clinical signs and body weight change." | 1.39 | Effectiveness of a hydroxynaphthoquinone fraction from Arnebia euchroma in rats with experimental colitis. ( Che, X; Fan, HY; Liu, K; Lv, WH; Song, WW; Xu, H; Yang, MY; Zhang, ZL, 2013) |
| "Mesalamine is a mainstay therapeutic agent in chronic ulcerative colitis (CUC) in which condition it reverses crypt architectural changes and reduces colitis-associated cancer (CAC)." | 1.36 | Mesalamine inhibits epithelial beta-catenin activation in chronic ulcerative colitis. ( Barrett, TA; Blatner, NR; Brown, JB; Cheresh, P; Dirisina, R; Goretsky, T; Grimm, GR; Khazaie, K; Lee, G; Li, L; Managlia, E; Yang, GY, 2010) |
| "Colitis was evaluated by means of the length of the colon, white blood cell count (WBC), tissue myeloperoxidase (MPO) activity, and histological inflammation scores." | 1.35 | Oral administration of mesalazine protects against mucosal injury and permeation in dextran sulfate sodium-induced colitis in rats. ( Aoyagi, K; Hayashi, Y; Morita, I; Sakisaka, S; Yamamoto, C, 2009) |
| "The number of neoplasms in the mice treated with 5-ASA was significantly lower than that in the control mice." | 1.34 | 5-aminosalicylic acid given in the remission stage of colitis suppresses colitis-associated cancer in a mouse colitis model. ( Endo, H; Fujisawa, T; Fujita, K; Ikeda, I; Inamori, M; Kubota, K; Nagashima, Y; Nakagama, H; Nakajima, A; Nozaki, Y; Saito, S; Takahashi, H; Tomimoto, A; Wada, K; Yoneda, M; Yonemitsu, K, 2007) |
| "We have developed a new experimental ulcerative colitis model in rats." | 1.31 | [The new experimental ulcerative colitis model in rats induced by subserosal injection of acetic acid]. ( Hamamoto, S; Iwadate, K; Kojima, R; Moriwaki, M; Ohwaki, T, 2001) |
| "A pharmacokinetic model of colon-specific drug delivery developed in a previous study has been validated by use of 5-aminosalicylic acid (5-ASA) as a model anti-inflammatory drug." | 1.30 | Validation of a pharmacokinetic model of colon-specific drug delivery and the therapeutic effects of chitosan capsules containing 5-aminosalicylic acid on 2,4,6-trinitrobenzenesulphonic acid-induced colitis in rats. ( Fujita, T; Muranishi, S; Odoriba, T; Okabe, S; Terabe, A; Tozaki, H; Yamamoto, A, 1999) |
| "An increased incidence of colonic cancer is associated with chronic inflammatory bowel disease." | 1.28 | The effect of therapeutic drugs used in inflammatory bowel disease on the incidence and growth of colonic cancer in the dimethylhydrazine rat model. ( Crouch, R; Davis, AE; Patterson, F, 1992) |
| "Drug treatment with sulfasalazine or 5-aminosalicylic acid improved enteritis score." | 1.28 | Chronic intrajejunal TNBS application in TNBS-sensitized rats: a new model of chronic inflammatory bowel diseases. ( Selve, N, 1992) |
| "The efficacy of various drugs used to treat ulcerative colitis, (sulfasalazine, 5-aminosalicylate, hydrocortisone) was investigated in a model of acetic acid-induced colitis in the rat." | 1.28 | Antiinflammatory effects of various drugs on acetic acid induced colitis in the rat. ( Bostwick, JS; Decktor, DL; Fitzpatrick, LR; Pendleton, RG; Renzetti, M, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.93) | 18.7374 |
| 1990's | 14 (13.08) | 18.2507 |
| 2000's | 26 (24.30) | 29.6817 |
| 2010's | 40 (37.38) | 24.3611 |
| 2020's | 26 (24.30) | 2.80 |
| Authors | Studies |
|---|---|
| Andrzejak, V | 1 |
| Muccioli, GG | 1 |
| Body-Malapel, M | 1 |
| El Bakali, J | 1 |
| Djouina, M | 1 |
| Renault, N | 1 |
| Chavatte, P | 1 |
| Desreumaux, P | 1 |
| Lambert, DM | 1 |
| Millet, R | 1 |
| Kadayat, TM | 2 |
| Banskota, S | 2 |
| Gurung, P | 2 |
| Bist, G | 2 |
| Thapa Magar, TB | 1 |
| Shrestha, A | 2 |
| Kim, JA | 2 |
| Lee, ES | 2 |
| Magar, TBT | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Rath, B | 1 |
| Abul Qais, F | 1 |
| Patro, R | 1 |
| Mohapatra, S | 1 |
| Sharma, T | 1 |
| Chen, H | 1 |
| Cui, J | 1 |
| Wang, J | 2 |
| Wang, Y | 2 |
| Tong, F | 1 |
| Tian, Y | 1 |
| Gong, Y | 1 |
| Ma, Y | 1 |
| Liu, L | 1 |
| Zhang, X | 2 |
| Kozhakhmetov, S | 1 |
| Babenko, D | 1 |
| Kozhakhmetova, S | 1 |
| Tuyakova, A | 1 |
| Nurgaziyev, M | 1 |
| Nurgozhina, A | 1 |
| Muhanbetganov, N | 1 |
| Chulenbayeva, L | 1 |
| Sergazy, S | 1 |
| Gulyayev, A | 1 |
| Aljofan, M | 1 |
| Kushugulova, A | 1 |
| Bai, B | 1 |
| Li, H | 3 |
| Han, L | 1 |
| Mei, Y | 1 |
| Hu, C | 1 |
| Mei, Q | 1 |
| Xu, J | 2 |
| Liu, X | 1 |
| Ashour, RH | 1 |
| Hazem, NM | 1 |
| AbdElfattah, AA | 1 |
| El-Kady, RA | 1 |
| Elmasry, A | 1 |
| Su, XL | 1 |
| Zhang, T | 1 |
| Guo, S | 1 |
| Wang, X | 4 |
| Chen, L | 2 |
| Wei, W | 1 |
| Huang, L | 1 |
| Zheng, J | 1 |
| Sun, G | 1 |
| Yang, H | 2 |
| Sun, X | 1 |
| Yao, X | 1 |
| Lin, A | 1 |
| Liu, H | 1 |
| Huang, S | 1 |
| Xie, X | 1 |
| Su, Y | 2 |
| Pan, Z | 1 |
| Li, Y | 3 |
| Liang, J | 1 |
| Zhang, M | 2 |
| Pan, S | 1 |
| Xu, B | 1 |
| Li, L | 2 |
| Chen, J | 1 |
| Luo, X | 1 |
| Zhou, L | 1 |
| Xia, S | 1 |
| Li, Z | 1 |
| Zhou, Y | 1 |
| Sun, S | 1 |
| Xu, X | 1 |
| Shao, J | 1 |
| Zhang, Z | 2 |
| Kong, D | 1 |
| Zhang, F | 1 |
| Zheng, S | 1 |
| Tange, K | 1 |
| Yagi, S | 1 |
| Takeshita, E | 1 |
| Abe, M | 1 |
| Yamamoto, Y | 1 |
| Tomida, H | 1 |
| Kawamura, T | 1 |
| Hanayama, M | 1 |
| Matsuura, B | 1 |
| Ikeda, Y | 1 |
| Hiasa, Y | 1 |
| Liu, YH | 2 |
| Rong, ZL | 2 |
| Zhu, HY | 2 |
| Li, YT | 2 |
| You, Y | 2 |
| Chung, KS | 1 |
| Park, SE | 1 |
| Lee, JH | 1 |
| Kim, SY | 2 |
| Han, HS | 1 |
| Lee, YS | 1 |
| Jung, SH | 1 |
| Jang, E | 1 |
| Lee, S | 1 |
| Lee, KT | 1 |
| Yue, LI | 1 |
| Shuting, W | 1 |
| Runyuan, Z | 1 |
| Dongmei, F | 1 |
| Dike, Z | 1 |
| Fengbin, L | 1 |
| Hong, MI | 1 |
| Liu, MR | 1 |
| Wei, LF | 1 |
| Liu, XT | 1 |
| An, ZT | 1 |
| Gu, LM | 1 |
| Tian, YZ | 1 |
| Cong, J | 1 |
| Wang, P | 1 |
| Gai, H | 1 |
| Zhou, S | 1 |
| Zhang, Y | 1 |
| Zhao, T | 1 |
| Wada, H | 1 |
| Miyoshi, J | 1 |
| Kuronuma, S | 1 |
| Nishinarita, Y | 1 |
| Oguri, N | 1 |
| Hibi, N | 1 |
| Takeuchi, O | 1 |
| Akimoto, Y | 1 |
| Lee, STM | 1 |
| Matsuura, M | 1 |
| Kobayashi, T | 1 |
| Hibi, T | 1 |
| Hisamatsu, T | 1 |
| Do, HJ | 1 |
| Kim, YS | 1 |
| Oh, TW | 1 |
| Krajewska, JB | 1 |
| Pietruszka, P | 1 |
| Tomczyk, D | 1 |
| Chen, C | 1 |
| Owczarek, A | 1 |
| Karolewicz, B | 1 |
| Czapor-Irzabek, H | 1 |
| Gorniak, A | 1 |
| Fichna, J | 1 |
| Thakur, V | 1 |
| Singh, A | 1 |
| Joshi, N | 1 |
| Mishra, N | 1 |
| De Caro, C | 1 |
| Leo, A | 1 |
| Nesci, V | 1 |
| Ghelardini, C | 1 |
| di Cesare Mannelli, L | 1 |
| Striano, P | 1 |
| Avagliano, C | 1 |
| Calignano, A | 1 |
| Mainardi, P | 1 |
| Constanti, A | 1 |
| Citraro, R | 1 |
| De Sarro, G | 1 |
| Russo, E | 1 |
| Lan, D | 1 |
| Wen, Y | 1 |
| Dong, X | 1 |
| Yang, Q | 1 |
| Liu, Y | 1 |
| Wang, K | 1 |
| Miao, Y | 1 |
| Xu, HM | 1 |
| Zhou, YL | 1 |
| Li, YF | 1 |
| Zhao, C | 1 |
| Huang, HL | 1 |
| Du, YL | 1 |
| He, J | 1 |
| Zhou, YJ | 1 |
| Nie, YQ | 1 |
| Han, Z | 1 |
| Wang, H | 1 |
| Guo, D | 1 |
| Zhang, J | 1 |
| Xu, W | 1 |
| Su, W | 2 |
| Xue, Z | 1 |
| Pu, F | 1 |
| Xie, Z | 1 |
| Jin, K | 1 |
| Polyakov, NE | 1 |
| Dushkin, AV | 1 |
| Zhou, W | 1 |
| Zhang, H | 1 |
| Pan, Y | 1 |
| Xu, Y | 1 |
| Cao, Y | 1 |
| Guo, Z | 1 |
| Bai, Y | 1 |
| Mei, H | 1 |
| Li, J | 1 |
| Pu, Y | 1 |
| Zhao, N | 1 |
| Gao, W | 1 |
| Wu, F | 1 |
| He, B | 1 |
| Xie, J | 1 |
| Newe, M | 1 |
| Kant, TA | 1 |
| Hoffmann, M | 1 |
| Rausch, JSE | 1 |
| Winter, L | 1 |
| Künzel, K | 1 |
| Klapproth, E | 1 |
| Günther, C | 1 |
| Künzel, SR | 1 |
| Varga, G | 1 |
| Ugocsai, M | 1 |
| Hartmann, P | 1 |
| Lajkó, N | 1 |
| Molnár, R | 1 |
| Szűcs, S | 1 |
| Jász, DK | 1 |
| Érces, D | 1 |
| Ghyczy, M | 1 |
| Tóth, G | 1 |
| Boros, M | 1 |
| Chiu, CT | 1 |
| Kuo, SN | 1 |
| Hung, SW | 1 |
| Yang, CY | 1 |
| Chen, YL | 1 |
| Zhang, YL | 1 |
| Dai, YC | 1 |
| Tang, ZP | 1 |
| Boeing, T | 1 |
| de Souza, P | 1 |
| Bonomini, TJ | 1 |
| Mariano, LNB | 1 |
| Somensi, LB | 1 |
| Lucinda, RM | 1 |
| Malheiros, A | 1 |
| da Silva, LM | 1 |
| Andrade, SF | 1 |
| Motta, JP | 1 |
| Allain, T | 1 |
| Green-Harrison, LE | 1 |
| Groves, RA | 1 |
| Feener, T | 1 |
| Ramay, H | 1 |
| Beck, PL | 1 |
| Lewis, IA | 1 |
| Wallace, JL | 4 |
| Buret, AG | 1 |
| Yang, Y | 1 |
| Kim, W | 1 |
| Kim, D | 1 |
| Jeong, S | 1 |
| Yoo, JW | 1 |
| Jung, Y | 1 |
| Newton, AMJ | 1 |
| Lakshmanan, P | 1 |
| Liu, Q | 1 |
| Tang, JH | 1 |
| Wen, JJ | 1 |
| Zhu, JQ | 1 |
| Chang, WC | 2 |
| Zenser, TV | 1 |
| Cooper, HS | 2 |
| Clapper, ML | 2 |
| Xue, LY | 1 |
| Ouyang, Q | 1 |
| Zhou, XG | 1 |
| Huang, ZH | 1 |
| Chen, W | 1 |
| Chen, M | 1 |
| Yu, LM | 1 |
| Jilani, JA | 1 |
| Shomaf, M | 1 |
| Alzoubi, KH | 1 |
| Fan, HY | 1 |
| Zhang, ZL | 1 |
| Liu, K | 1 |
| Yang, MY | 1 |
| Lv, WH | 1 |
| Che, X | 1 |
| Xu, H | 1 |
| Song, WW | 1 |
| Sang, LX | 1 |
| Chang, B | 1 |
| Dai, C | 1 |
| Gao, N | 1 |
| Liu, WX | 1 |
| Jiang, M | 1 |
| Vishwakarma, N | 1 |
| Ganeshpurkar, A | 1 |
| Pandey, V | 1 |
| Dubey, N | 1 |
| Bansal, D | 1 |
| Xu, M | 1 |
| Sun, M | 1 |
| Qiao, H | 1 |
| Ping, Q | 1 |
| Elamin, ES | 1 |
| Min, JK | 1 |
| Lee, CH | 1 |
| Jang, SE | 1 |
| Park, JW | 1 |
| Lim, SJ | 1 |
| Kim, DH | 1 |
| Bae, H | 1 |
| Kim, HJ | 1 |
| Cha, JM | 1 |
| Yamada, S | 1 |
| Koyama, T | 1 |
| Noguchi, H | 1 |
| Ueda, Y | 1 |
| Kitsuyama, R | 1 |
| Shimizu, H | 1 |
| Tanimoto, A | 1 |
| Wang, KY | 1 |
| Nawata, A | 1 |
| Nakayama, T | 1 |
| Sasaguri, Y | 1 |
| Satoh, T | 1 |
| Kortüm, B | 1 |
| Campregher, C | 1 |
| Lang, M | 1 |
| Khare, V | 1 |
| Pinter, M | 1 |
| Evstatiev, R | 1 |
| Schmid, G | 1 |
| Mittlböck, M | 1 |
| Scharl, T | 1 |
| Kucherlapati, MH | 1 |
| Edelmann, W | 1 |
| Gasche, C | 1 |
| Zhang, HX | 2 |
| Zhu, B | 1 |
| Fu, XX | 1 |
| Zeng, JC | 1 |
| Zhang, JA | 1 |
| Wang, WD | 1 |
| Kong, B | 1 |
| Xiang, WY | 1 |
| Zhong, J | 1 |
| Wang, CY | 1 |
| Zheng, XB | 1 |
| Xu, JF | 1 |
| Sawarkar, SP | 1 |
| Deshpande, SG | 1 |
| Bajaj, AN | 1 |
| Nikam, VS | 1 |
| Li, YH | 1 |
| Xiao, HT | 1 |
| Fu, HB | 1 |
| Ho, A | 1 |
| Lin, CY | 1 |
| Huang, Y | 1 |
| Lin, G | 1 |
| Bian, ZX | 1 |
| Do, EJ | 1 |
| Hwang, SW | 1 |
| Ryu, YM | 1 |
| Cho, EA | 1 |
| Chung, EJ | 1 |
| Park, S | 1 |
| Lee, HJ | 1 |
| Byeon, JS | 1 |
| Ye, BD | 1 |
| Yang, DH | 1 |
| Park, SH | 1 |
| Yang, SK | 1 |
| Kim, JH | 1 |
| Myung, SJ | 1 |
| Dai, ZH | 1 |
| Tan, B | 1 |
| Wang, O | 1 |
| Qian, JM | 1 |
| Lv, H | 1 |
| Zeeff, SB | 1 |
| Kunne, C | 1 |
| Bouma, G | 1 |
| de Vries, RB | 1 |
| Te Velde, AA | 1 |
| Simon, H | 1 |
| Fischer, T | 1 |
| Almási, A | 1 |
| Fischer, E | 1 |
| Zhao, HM | 1 |
| Xu, R | 1 |
| Huang, XY | 1 |
| Cheng, SM | 1 |
| Huang, MF | 1 |
| Yue, HY | 1 |
| Zou, Y | 1 |
| Lu, AP | 1 |
| Liu, DY | 1 |
| Izzo, R | 1 |
| Figliuzzi, MM | 1 |
| Monteleone, G | 1 |
| Duan, H | 1 |
| Lü, S | 1 |
| Qin, H | 1 |
| Gao, C | 1 |
| Bai, X | 1 |
| Wei, Y | 1 |
| Wu, X | 1 |
| Liu, M | 1 |
| Liu, Z | 1 |
| Tang, H | 1 |
| Xiang, D | 1 |
| Wang, F | 1 |
| Mao, J | 1 |
| Tan, X | 1 |
| Requena, P | 1 |
| Daddaoua, A | 1 |
| Martínez-Plata, E | 1 |
| González, M | 1 |
| Zarzuelo, A | 1 |
| Suárez, MD | 1 |
| Sánchez de Medina, F | 1 |
| Martínez-Augustin, O | 1 |
| Ancha, HR | 1 |
| Kurella, RR | 1 |
| McKimmey, CC | 1 |
| Lightfoot, S | 2 |
| Harty, RF | 2 |
| Hirotani, Y | 1 |
| Mikajiri, K | 1 |
| Ikeda, K | 1 |
| Myotoku, M | 1 |
| Kurokawa, N | 1 |
| Moulari, B | 1 |
| Pertuit, D | 1 |
| Pellequer, Y | 1 |
| Lamprecht, A | 1 |
| Chen, Y | 2 |
| Liu, WL | 1 |
| Zhou, TH | 1 |
| Cai, JT | 1 |
| Du, Q | 1 |
| Wang, LJ | 1 |
| Wu, JG | 1 |
| Si, JM | 1 |
| Zhang, HQ | 1 |
| Ding, TT | 1 |
| Zhao, JS | 1 |
| Yang, X | 1 |
| Zhang, JJ | 1 |
| Cui, YL | 1 |
| Brown, JB | 1 |
| Lee, G | 1 |
| Managlia, E | 1 |
| Grimm, GR | 1 |
| Dirisina, R | 1 |
| Goretsky, T | 1 |
| Cheresh, P | 1 |
| Blatner, NR | 1 |
| Khazaie, K | 1 |
| Yang, GY | 1 |
| Barrett, TA | 1 |
| Hayashi, Y | 1 |
| Aoyagi, K | 1 |
| Morita, I | 1 |
| Yamamoto, C | 1 |
| Sakisaka, S | 1 |
| Saijo, F | 1 |
| Milsom, AB | 1 |
| Bryan, NS | 1 |
| Bauer, SM | 1 |
| Vowinkel, T | 1 |
| Ivanovic, M | 1 |
| Andry, C | 1 |
| Granger, DN | 1 |
| Rodriguez, J | 1 |
| Feelisch, M | 1 |
| Fleming, A | 1 |
| Jankowski, J | 1 |
| Goldsmith, P | 1 |
| Varshosaz, J | 1 |
| Emami, J | 1 |
| Ahmadi, F | 1 |
| Tavakoli, N | 1 |
| Minaiyan, M | 1 |
| Fassihi, A | 1 |
| Mahzouni, P | 1 |
| Dorkoosh, F | 1 |
| Jagtap, AG | 1 |
| Niphadkar, PV | 1 |
| Phadke, AS | 1 |
| Mura, C | 1 |
| Nácher, A | 1 |
| Merino, V | 1 |
| Merino-Sanjuan, M | 1 |
| Carda, C | 1 |
| Ruiz, A | 1 |
| Manconi, M | 1 |
| Loy, G | 1 |
| Fadda, AM | 1 |
| Diez-Sales, O | 1 |
| Holtmann, MH | 1 |
| Galle, PR | 1 |
| Reifen, R | 1 |
| Nissenkorn, A | 1 |
| Matas, Z | 1 |
| Bujanover, Y | 1 |
| Kles, KA | 1 |
| Vavricka, SR | 1 |
| Turner, JR | 1 |
| Musch, MW | 1 |
| Hanauer, SB | 1 |
| Chang, EB | 1 |
| An, MM | 1 |
| Fan, KX | 1 |
| Zhang, JD | 1 |
| Li, HJ | 1 |
| Song, SC | 1 |
| Liu, BG | 1 |
| Gao, PH | 1 |
| Zhou, Q | 1 |
| Jiang, YY | 1 |
| Nakashima, T | 1 |
| Maeda, T | 1 |
| Nagamoto, H | 1 |
| Kumakura, T | 1 |
| Takai, M | 1 |
| Mori, T | 1 |
| D'Argenio, G | 1 |
| Valenti, M | 1 |
| Scaglione, G | 1 |
| Cosenza, V | 1 |
| Sorrentini, I | 1 |
| Di Marzo, V | 1 |
| Gorgulu, S | 1 |
| Yagci, G | 1 |
| Kaymakcioglu, N | 1 |
| Ozkara, M | 1 |
| Kurt, B | 1 |
| Ozcan, A | 1 |
| Kaya, O | 1 |
| Sadir, S | 1 |
| Tufan, T | 1 |
| Siddiqui, A | 1 |
| Ancha, H | 1 |
| Tedesco, D | 1 |
| Stewart, CA | 1 |
| Korkut, C | 1 |
| Asoglu, O | 1 |
| Aksoy, M | 1 |
| Kapran, Y | 1 |
| Bilge, H | 1 |
| Kiremit-Korkut, N | 1 |
| Parlak, M | 1 |
| Fiorucci, S | 2 |
| Orlandi, S | 1 |
| Mencarelli, A | 1 |
| Caliendo, G | 1 |
| Santagada, V | 1 |
| Distrutti, E | 1 |
| Santucci, L | 1 |
| Cirino, G | 1 |
| Nandi, J | 1 |
| Saud, B | 1 |
| Zinkievich, JM | 1 |
| Palma, DT | 1 |
| Levine, RA | 1 |
| Zhao, L | 1 |
| Han, T | 1 |
| Chen, S | 1 |
| Ikeda, I | 1 |
| Tomimoto, A | 1 |
| Wada, K | 1 |
| Fujisawa, T | 1 |
| Fujita, K | 1 |
| Yonemitsu, K | 1 |
| Nozaki, Y | 1 |
| Endo, H | 1 |
| Takahashi, H | 1 |
| Yoneda, M | 1 |
| Inamori, M | 1 |
| Kubota, K | 1 |
| Saito, S | 1 |
| Nagashima, Y | 1 |
| Nakagama, H | 1 |
| Nakajima, A | 1 |
| Horváth, K | 1 |
| Varga, C | 1 |
| Berkó, A | 1 |
| Pósa, A | 1 |
| László, F | 1 |
| Whittle, BJ | 1 |
| Gary, MA | 1 |
| Coudry, RA | 1 |
| Litwin, S | 1 |
| Devarajan, K | 1 |
| Lubet, RA | 1 |
| Luck, MS | 1 |
| Bass, P | 1 |
| Millar, AD | 1 |
| Rampton, DS | 1 |
| Chander, CL | 1 |
| Claxson, AW | 1 |
| Blades, S | 1 |
| Coumbe, A | 1 |
| Panetta, J | 1 |
| Morris, CJ | 1 |
| Blake, DR | 1 |
| Murthy, S | 1 |
| Hui-Qi, Q | 1 |
| Sakai, T | 1 |
| Depace, DE | 1 |
| Fondacaro, JD | 1 |
| Ekström, GM | 1 |
| Robert, FS | 1 |
| Rao, JP | 1 |
| Cutrufo, C | 1 |
| Evangelista, S | 1 |
| Cirillo, R | 1 |
| Ciucci, A | 1 |
| Conte, B | 1 |
| Lopez, G | 1 |
| Manzini, S | 1 |
| Maggi, CA | 1 |
| Vergnolle, N | 1 |
| Muscará, MN | 1 |
| Asfaha, S | 1 |
| Chapman, K | 1 |
| McKnight, W | 1 |
| Del Soldato, P | 1 |
| Morelli, A | 1 |
| Tozaki, H | 1 |
| Fujita, T | 1 |
| Odoriba, T | 1 |
| Terabe, A | 1 |
| Okabe, S | 1 |
| Muranishi, S | 1 |
| Yamamoto, A | 1 |
| Brown, WA | 1 |
| Farmer, KC | 1 |
| Skinner, SA | 1 |
| Malcontenti-Wilson, C | 1 |
| Misajon, A | 1 |
| O'Brien, PE | 1 |
| Kojima, R | 1 |
| Hamamoto, S | 1 |
| Moriwaki, M | 1 |
| Iwadate, K | 1 |
| Ohwaki, T | 1 |
| Goto, M | 1 |
| Okamoto, Y | 1 |
| Yamamoto, M | 1 |
| Aki, H | 1 |
| Rachmilewitz, D | 1 |
| Karmeli, F | 1 |
| Schwartz, LW | 1 |
| Simon, PL | 1 |
| Davis, AE | 1 |
| Patterson, F | 1 |
| Crouch, R | 1 |
| Selve, N | 1 |
| Rask-Madsen, J | 1 |
| Bukhave, K | 1 |
| Laursen, LS | 1 |
| Lauritsen, K | 1 |
| Hansen, PR | 1 |
| Svendsen, JH | 1 |
| Høst, NB | 1 |
| Hansen, SH | 1 |
| Haunsø, S | 1 |
| Fitzpatrick, LR | 1 |
| Bostwick, JS | 1 |
| Renzetti, M | 1 |
| Pendleton, RG | 1 |
| Decktor, DL | 1 |
| Donowitz, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| "Azione Chemiopreventiva Della Mesalazina Sul Cancro Del Colon-retto: Studio Pilota Per la Valutazione Degli Effetti Molecolari in Vivo Sulla Via di Segnalazione Proliferativa Della β-catenina (Official Title in Italian Language)"[NCT02077777] | Phase 2 | 21 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for mesalamine and Disease Models, Animal
| Article | Year |
|---|---|
Differential response of flat and polypoid colitis-associated colorectal neoplasias to chemopreventive agents and heterocyclic amines.
Topics: Amines; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Carcinogens; Cell Proliferation | 2013 |
Actual Usage and Quality of Experimental Colitis Models in Preclinical Efficacy Testing: A Scoping Review.
Topics: Adrenal Cortex Hormones; Animals; Anti-Inflammatory Agents, Non-Steroidal; Biomedical Research; Coli | 2016 |
Nitric oxide-releasing mesalamine: potential utility for treatment of inflammatory bowel disease.
Topics: Aminosalicylic Acids; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Colitis; Cytokine | 2003 |
Current concept of pathophysiological understanding and natural course of ulcerative colitis.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Animals; Anti-Inflammatory Agents, Non-Steroidal; Colect | 2004 |
5-Lipoxygenase inhibitors for the treatment of inflammatory bowel disease.
Topics: Adrenal Cortex Hormones; Aminosalicylic Acids; Animals; Arachidonic Acid; Disease Models, Animal; Do | 1992 |
1 trial available for mesalamine and Disease Models, Animal
| Article | Year |
|---|---|
5-Lipoxygenase inhibitors for the treatment of inflammatory bowel disease.
Topics: Adrenal Cortex Hormones; Aminosalicylic Acids; Animals; Arachidonic Acid; Disease Models, Animal; Do | 1992 |
102 other studies available for mesalamine and Disease Models, Animal
| Article | Year |
|---|---|
New FAAH inhibitors based on 3-carboxamido-5-aryl-isoxazole scaffold that protect against experimental colitis.
Topics: Amidohydrolases; Animals; Colitis; Disease Models, Animal; Enzyme Activation; Enzyme Inhibitors; Hum | 2011 |
Discovery and structure-activity relationship studies of 2-benzylidene-2,3-dihydro-1H-inden-1-one and benzofuran-3(2H)-one derivatives as a novel class of potential therapeutics for inflammatory bowel disease.
Topics: Animals; Benzofurans; Colitis; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Discov | 2017 |
Synthesis and biological evaluation of pyridine-linked indanone derivatives: Potential agents for inflammatory bowel disease.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Adhesion; Colitis; Dise | 2018 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Design, synthesis and molecular modeling studies of novel mesalamine linked coumarin for treatment of inflammatory bowel disease.
Topics: Acetic Acid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Coumarins; Disease Models, Animal; Do | 2021 |
5‑Aminosalicylic acid attenuates paraquat‑induced lung fibroblast activation and pulmonary fibrosis of rats.
Topics: Acute Lung Injury; Animals; Disease Models, Animal; Fibroblasts; Humans; Lung; Male; Mesalamine; Par | 2022 |
Therapeutic Potential of Metabolites from
Topics: Animals; Colitis, Ulcerative; Cytokines; Dextran Sulfate; Disease Models, Animal; Dysbiosis; Gastroi | 2022 |
Molecular mechanism of the TGF‑β/Smad7 signaling pathway in ulcerative colitis.
Topics: Animals; Cadherins; Colitis, Ulcerative; Colon; Dextran Sulfate; Disease Models, Animal; Female; Int | 2022 |
Pentosan Polysulfate Sodium augments the therapeutic effect of 5-Aminosalicylic Acid in DSS colitis model; the role of IL-35 expression.
Topics: Animals; Colitis; Colitis, Ulcerative; Colon; Dextran Sulfate; Disease Models, Animal; Female; Inter | 2022 |
Efficacy of Wumei Baijiang prescription on regulatory T cells / helper T cells Immune balance in mice with ulcerative coliti.
Topics: Animals; Body Weight; Colitis, Ulcerative; Colon; Disease Models, Animal; Drugs, Chinese Herbal; Int | 2022 |
5-Aminosalicylic acid ameliorates dextran sulfate sodium-induced colitis in mice by modulating gut microbiota and bile acid metabolism.
Topics: Animals; Bile Acids and Salts; Colitis; Colon; Dextran Sulfate; Disease Models, Animal; Gastrointest | 2022 |
Dahuang Mudan decoction repairs intestinal barrier in chronic colitic mice by regulating the function of ILC3.
Topics: Animals; Body Weight; Caco-2 Cells; Claudin-1; Colitis; Colitis, Ulcerative; Culture Media, Conditio | 2022 |
Qingchang Wenzhong Decoction reduce ulcerative colitis in mice by inhibiting Th17 lymphocyte differentiation.
Topics: Animals; Colitis, Ulcerative; Colon; Dextran Sulfate; Disease Models, Animal; Inflammation; Interleu | 2022 |
Oral administration of human carbonic anhydrase I suppresses colitis in a murine inflammatory bowel disease model.
Topics: Administration, Oral; Animals; Carbonic Anhydrase I; Colitis; Disease Models, Animal; Humans; Inflam | 2022 |
[Mechanism of Shenling Baizhu Powder on treatment of ulcerative colitis based on NLRP3 inflammatory].
Topics: Animals; Caspase 1; Colitis; Colitis, Ulcerative; Colon; Cytokines; Dextran Sulfate; Disease Models, | 2022 |
[Mechanism of Shenling Baizhu Powder on treatment of ulcerative colitis based on NLRP3 inflammatory].
Topics: Animals; Caspase 1; Colitis; Colitis, Ulcerative; Colon; Cytokines; Dextran Sulfate; Disease Models, | 2022 |
[Mechanism of Shenling Baizhu Powder on treatment of ulcerative colitis based on NLRP3 inflammatory].
Topics: Animals; Caspase 1; Colitis; Colitis, Ulcerative; Colon; Cytokines; Dextran Sulfate; Disease Models, | 2022 |
[Mechanism of Shenling Baizhu Powder on treatment of ulcerative colitis based on NLRP3 inflammatory].
Topics: Animals; Caspase 1; Colitis; Colitis, Ulcerative; Colon; Cytokines; Dextran Sulfate; Disease Models, | 2022 |
Protective effect of 7-hydroxyl-1-methylindole-3-acetonitrile on the intestinal mucosal damage response to inflammation in mice with DSS-induced colitis.
Topics: Animals; Colitis; Colitis, Ulcerative; Colon; Dextran Sulfate; Disease Models, Animal; Drinking Wate | 2023 |
Efficacy of active ingredients in Qingdai on ulcerative colitis: a network pharmacology-based evaluation.
Topics: Animals; Colitis; Colitis, Ulcerative; Colon; Disease Models, Animal; Glycogen Synthase Kinase 3; Me | 2023 |
[Effects of Huangqin Tang on NLRP3/Caspase-1 pathway in mice model of ulcerative colitis].
Topics: Animals; Caspase 1; Colitis, Ulcerative; Colon; Dextran Sulfate; Disease Models, Animal; Drugs, Chin | 2023 |
Effects of compound prebiotics as prophylactic and therapeutic supplementation in a mouse model of acute colitis.
Topics: Animals; Colitis; Colon; Disease Models, Animal; Mesalamine; Mice; Mice, Inbred C57BL; Phylogeny; Pr | 2023 |
5-Aminosalicylic acid alters the gut microbiota and altered microbiota transmitted vertically to offspring have protective effects against colitis.
Topics: Animals; Anti-Inflammatory Agents; Colitis; Colitis, Ulcerative; Colon; Dextran Sulfate; Disease Mod | 2023 |
Effect of Polycan, a β-Glucan from
Topics: Animals; beta-Glucans; Colitis; Colitis, Ulcerative; Colon; Dextran Sulfate; Dextrans; Disease Model | 2023 |
Evaluation of the effect of liposomes loaded with chlorogenic acid in treatment of 2,4,6-trinitrobenzenesulfonic acid-induced murine colitis.
Topics: Animals; Anti-Inflammatory Agents; Chlorogenic Acid; Colitis; Colon; Disease Models, Animal; Inflamm | 2019 |
Spray dried formulation of mesalamine embedded with probiotic biomass for the treatment of ulcerative colitis:
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzenesulfonates; Caco-2 Cells; Colitis, Ulcerati | 2019 |
Intestinal inflammation increases convulsant activity and reduces antiepileptic drug efficacy in a mouse model of epilepsy.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticonvulsants; Colitis; Convulsants; Dextran Sul | 2019 |
The endogenous ligand for guanylate cyclase-C activation reliefs intestinal inflammation in the DSS colitis model.
Topics: Animals; Colitis, Ulcerative; Colon; Cytokines; Dextran Sulfate; Disease Models, Animal; Enzyme Acti | 2020 |
Inhibition of PD-1 Protects against TNBS-Induced Colitis via Alteration of Enteric Microbiota.
Topics: Animals; Colitis; Colon; Disease Models, Animal; Gastrointestinal Microbiome; Immune Checkpoint Inhi | 2021 |
Integrative transcriptomic and metabonomic profiling analyses reveal the molecular mechanism of Chinese traditional medicine huankuile suspension on TNBS-induced ulcerative colitis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Cytokines; Disease Models, An | 2021 |
Research on Preparation of 5-ASA Colon-Specific Hydrogel Delivery System without Crosslinking Agent by Mechanochemical Method.
Topics: Administration, Oral; Alginates; Animals; Biological Availability; Chemistry, Pharmaceutical; Chitos | 2021 |
circRNA expression profiling of colon tissue from mesalazine-treated mouse of inflammatory bowel disease reveals an important circRNA-miRNA-mRNA pathway.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Colon; Disease Models, Animal; Gene Expression Pro | 2021 |
Thermosensitive polymer hydrogel as a physical shield on colonic mucosa for colitis treatment.
Topics: Animals; Biocompatible Materials; Colitis; Disease Models, Animal; Drug Carriers; Drug Liberation; H | 2021 |
Systemic mesalazine treatment prevents spontaneous skin fibrosis in PLK2-deficient mice.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Differentiation; Collagen; Creatinine; Diseas | 2021 |
Acetylsalicylic acid-tris-hydroxymethyl-aminomethane reduces colon mucosal damage without causing gastric side effects in a rat model of colitis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colitis; Colon; Disease Models, Animal; I | 2018 |
Combined Treatment with Hyaluronic Acid and Mesalamine Protects Rats from Inflammatory Bowel Disease Induced by Intracolonic Administration of Trinitrobenzenesulfonic Acid.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2; Cytokines; Disease Models, Anima | 2017 |
Systems pharmacology approach reveals the antiinflammatory effects of
Topics: Ampelopsis; Animals; Anti-Inflammatory Agents; Colitis, Ulcerative; Colon; Dextran Sulfate; Disease | 2018 |
Antioxidant and anti-inflammatory effect of plumieride in dextran sulfate sodium-induced colitis in mice.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Apocynaceae; Cell Line; Colitis; Colitis, Ulcerativ | 2018 |
Iron Sequestration in Microbiota Biofilms As A Novel Strategy for Treating Inflammatory Bowel Disease.
Topics: Adult; Animals; Bacterial Physiological Phenomena; Biofilms; Case-Control Studies; Disease Models, A | 2018 |
A colon-specific prodrug of metoclopramide ameliorates colitis in an experimental rat model.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Azo Compounds; Benzenesulfon | 2019 |
Comparative Efficacy of Chitosan, Pectin Based Mesalamine Colon Targeted Drug Delivery Systems on TNBS-induced IBD Model Rats.
Topics: Animals; Anti-Inflammatory Agents; Chitosan; Colon; Disease Models, Animal; Drug Delivery Systems; H | 2020 |
Regulatory mechanism of mesalazine on TLR4/MyD88-dependent pathway in mouse ulcerative colitis model.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Colitis, Ulcerative; Colon; Disease | 2019 |
Bacterial immune interaction in experimental colitis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Bacteria; Colitis, Ulcerative; Colon; Disease Mode | 2013 |
Synthesis and evaluation of mutual azo prodrug of 5-aminosalicylic acid linked to 2-phenylbenzoxazole-2-yl-5-acetic acid in ulcerative colitis.
Topics: Acetates; Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzoxazoles; Colitis, Ulcerative; Disea | 2013 |
Effectiveness of a hydroxynaphthoquinone fraction from Arnebia euchroma in rats with experimental colitis.
Topics: Animals; Anti-Inflammatory Agents; Boraginaceae; Colitis, Ulcerative; Colon; Disease Models, Animal; | 2013 |
Heat-killed VSL#3 ameliorates dextran sulfate sodium (DSS)-induced acute experimental colitis in rats.
Topics: Acute Disease; Animals; Colitis; Dextran Sulfate; Disease Models, Animal; Hot Temperature; Interleuk | 2013 |
Mesalazine-probiotics beads for acetic acid experimental colitis: formulation and characterization of a promising new therapeutic strategy for ulcerative colitis.
Topics: Acetic Acid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Survival; Colitis, Ulcerative; C | 2015 |
Preparation and evaluation of colon adhesive pellets of 5-aminosalicylic acid.
Topics: Acrylic Resins; Adhesiveness; Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal | 2014 |
Amelioration of trinitrobenzene sulfonic acid-induced colitis in mice by liquiritigenin.
Topics: Animals; Anti-Inflammatory Agents; Colitis; Colon; Cytokines; Disease Models, Animal; Dose-Response | 2015 |
Marine hydroquinone zonarol prevents inflammation and apoptosis in dextran sulfate sodium-induced mice ulcerative colitis.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents; Apoptosis; Cell Line; Colitis, Ulcerative; | 2014 |
Mesalazine and thymoquinone attenuate intestinal tumour development in Msh2(loxP/loxP) Villin-Cre mice.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzoquinones; Cell Proliferation; Colorectal Neop | 2015 |
BTLA associates with increased Foxp3 expression in CD4(+) T cells in dextran sulfate sodium-induced colitis.
Topics: Animals; CD4-Positive T-Lymphocytes; Colitis, Ulcerative; Colon; Dextran Sulfate; Disease Models, An | 2015 |
In Vivo Evaluation of 5-ASA Colon-Specific Tablets Using Experimental-Induced Colitis Rat Animal Model.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Chemistry, Pharmaceutical; C | 2015 |
Addition of Berberine to 5-Aminosalicylic Acid for Treatment of Dextran Sulfate Sodium-Induced Chronic Colitis in C57BL/6 Mice.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Berberine; Cells, Cultured; Colitis, Ulcerative; C | 2015 |
Suppression of colitis-associated carcinogenesis through modulation of IL-6/STAT3 pathway by balsalazide and VSL#3.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Azoxymethane; bcl-2-Assoc | 2016 |
1,25-hydroxyvitamin D relieves colitis in rats via down-regulation of toll-like receptor 9 expression.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Colitis; Disease Models, Animal; Down-Regulation; | 2015 |
Effects of Mesalazine on Morphological and Functional Changes in the Indomethacin-Induced Inflammatory Bowel Disease (Rat Model of Crohn's Disease).
Topics: Animals; Crohn Disease; Disease Models, Animal; Glucuronates; Indomethacin; Inflammation; Inflammato | 2017 |
Curcumin improves regulatory T cells in gut-associated lymphoid tissue of colitis mice.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colon; Curcumin; Cytokines; D | 2016 |
Sphingosine-1-phosphate receptor: a novel therapeutic target in ulcerative colitis.
Topics: Animals; Antibodies, Monoclonal; Colitis, Ulcerative; Disease Models, Animal; Humans; Mesalamine; Mi | 2016 |
Co-delivery of zinc and 5-aminosalicylic acid from alginate/N-succinyl-chitosan blend microspheres for synergistic therapy of colitis.
Topics: Administration, Oral; Alginates; Animals; Anti-Inflammatory Agents, Non-Steroidal; Chitosan; Colitis | 2017 |
5-ASA-loaded SiO2 nanoparticles-a novel drug delivery system targeting therapy on ulcerative colitis in mice.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Line; Cell Survival; Colitis, Ulcerative; Cyt | 2017 |
Bovine glycomacropeptide ameliorates experimental rat ileitis by mechanisms involving downregulation of interleukin 17.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents; Cattle; Disease Models, Animal; Down-Regula | 2008 |
Luminal antioxidants enhance the effects of mesalamine in the treatment of chemically induced colitis in rats.
Topics: Animals; Antioxidants; Ascorbic Acid; Colitis; Cyclic N-Oxides; Disease Models, Animal; Drug Synergi | 2008 |
Changes of the peptide YY levels in the intestinal tissue of rats with experimental colitis following oral administration of mesalazine and prednisolone.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Co | 2008 |
The targeting of surface modified silica nanoparticles to inflamed tissue in experimental colitis.
Topics: Animals; Caco-2 Cells; Cell Line; Colitis; Colon; Disease Models, Animal; Drug Carriers; Drug Delive | 2008 |
Therapeutic effects of rectal administration of muscovite on experimental colitis in rats.
Topics: Administration, Rectal; Aluminum Silicates; Animals; Anti-Inflammatory Agents; Body Weight; Colitis; | 2009 |
Therapeutic effects of Clostridium butyricum on experimental colitis induced by oxazolone in rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Butyrates; Calcitonin Gene-Related Peptide; Clostr | 2009 |
Mesalamine inhibits epithelial beta-catenin activation in chronic ulcerative colitis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; beta Catenin; Biopsy; Cell Proliferation; Colitis, | 2010 |
Oral administration of mesalazine protects against mucosal injury and permeation in dextran sulfate sodium-induced colitis in rats.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Colitis; Dextran Sulfate; Di | 2009 |
On the dynamics of nitrite, nitrate and other biomarkers of nitric oxide production in inflammatory bowel disease.
Topics: Animals; Biomarkers; Disease Models, Animal; Inflammatory Bowel Diseases; Male; Mesalamine; Nitrates | 2010 |
In vivo analysis of gut function and disease changes in a zebrafish larvae model of inflammatory bowel disease: a feasibility study.
Topics: Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Disease Models, Animal; | 2010 |
Preparation of budesonide-dextran conjugates using glutarate spacer as a colon-targeted drug delivery system: in vitro/in vivo evaluation in induced ulcerative colitis.
Topics: Administration, Oral; Anhydrides; Animals; Anti-Inflammatory Agents; Budesonide; Colitis, Ulcerative | 2011 |
Protective effect of aqueous extract of Bombax malabaricum DC on experimental models of inflammatory bowel disease in rats and mice.
Topics: Acetic Acid; Animals; Bombax; Colitis; Disease Models, Animal; Female; India; Indomethacin; Inflamma | 2011 |
N-Succinyl-chitosan systems for 5-aminosalicylic acid colon delivery: in vivo study with TNBS-induced colitis model in rats.
Topics: Absorption; Animals; Anti-Inflammatory Agents, Non-Steroidal; Chitosan; Colitis; Colon; Disease Mode | 2011 |
5-ASA and lycopene decrease the oxidative stress and inflammation induced by iron in rats with colitis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; beta Carotene; Carotenoids; Colitis; | 2004 |
Comparative analysis of the in vitro prosecretory effects of balsalazide, sulfasalazine, olsalazine, and mesalamine in rabbit distal ileum.
Topics: Aminosalicylic Acids; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Colitis, | 2005 |
Lymphtoxin beta receptor-Ig ameliorates TNBS-induced colitis via blocking LIGHT/HVEM signaling.
Topics: Animals; CD4-Positive T-Lymphocytes; Colitis; Colon; Disease Models, Animal; Gene Expression Regulat | 2005 |
Rebamipide enema is effective for treatment of experimental dextran sulfate sodium induced colitis in rats.
Topics: Alanine; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Colitis, Ulcerative; D | 2005 |
Up-regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation.
Topics: Adult; Aged; Amidohydrolases; Animals; Arachidonic Acids; Benzenesulfonates; Colitis; Colitis, Ulcer | 2006 |
Hyperbaric oxygen enhances the efficiency of 5-aminosalicylic acid in acetic acid-induced colitis in rats.
Topics: Acetic Acid; Animals; Colitis, Ulcerative; Combined Modality Therapy; Disease Models, Animal; Female | 2006 |
Antioxidant therapy with N-acetylcysteine plus mesalamine accelerates mucosal healing in a rodent model of colitis.
Topics: Acetylcysteine; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Biopsy, Needle; Coli | 2006 |
Histopathological comparison of topical therapy modalities for acute radiation proctitis in an experimental rat model.
Topics: Administration, Topical; Animals; Anti-Inflammatory Agents; Anti-Ulcer Agents; Betamethasone; Diseas | 2006 |
Enhanced activity of a hydrogen sulphide-releasing derivative of mesalamine (ATB-429) in a mouse model of colitis.
Topics: Animals; Anti-Inflammatory Agents; Chemokines; Colitis; Colon; Cytokines; Disease Models, Animal; Di | 2007 |
5-aminosalicylic acid improves indomethacin-induced enteropathy by inhibiting iNOS transcription in rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Blotting, Western; Cyclooxygenase Inhi | 2008 |
Protective effects of 2,3,5,4'-tetrahydroxystilbene-2-O-beta-d-glucoside, an active component of Polygonum multiflorum Thunb, on experimental colitis in mice.
Topics: Acetic Acid; Acute Disease; Animals; Anti-Inflammatory Agents; Antioxidants; Chronic Disease; Coliti | 2008 |
5-aminosalicylic acid given in the remission stage of colitis suppresses colitis-associated cancer in a mouse colitis model.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Body Weight; Colitis; Colitis, Ulcerative; Disease | 2007 |
The involvement of heme oxygenase-1 activity in the therapeutic actions of 5-aminosalicylic acid in rat colitis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Blotting, Western; Colitis; Disease | 2008 |
5-aminosalicylic acid inhibits colitis-associated colorectal dysplasias in the mouse model of azoxymethane/dextran sulfate sodium-induced colitis.
Topics: Animals; Azoxymethane; Colitis; Colorectal Neoplasms; Cyclooxygenase 2; Dextran Sulfate; Disease Mod | 2008 |
Effect of epidermal growth factor on experimental colitis in the rat.
Topics: Aminosalicylic Acids; Animals; Colitis; Colon; Disease Models, Animal; Eicosanoids; Epidermal Growth | 1993 |
Evaluating the antioxidant potential of new treatments for inflammatory bowel disease using a rat model of colitis.
Topics: Acetic Acid; Aminosalicylic Acids; Animals; Antioxidants; Butylated Hydroxytoluene; Colitis; Colitis | 1996 |
Ischemia/reperfusion injury in the rat colon.
Topics: 6-Ketoprostaglandin F1 alpha; Aerobiosis; Aminosalicylic Acids; Anaerobiosis; Animals; Antioxidants; | 1997 |
Oxazolone-induced colitis in rats: effects of budesonide, cyclosporin A, and 5-aminosalicylic acid.
Topics: Animals; Budesonide; Colitis; Colon; Cyclosporine; Disease Models, Animal; Female; Intestinal Mucosa | 1998 |
Mechanism of purgative effect of magnesium sulphate on mouse colon.
Topics: Animals; Anthracenes; Cathartics; Chloride Channels; Colon; Diarrhea; Disease Models, Animal; Drug I | 1997 |
Effect of MEN 11467, a new tachykinin NK1 receptor antagonist, in acute rectocolitis induced by acetic acid in guinea-pigs.
Topics: Acetic Acid; Acute Disease; Administration, Rectal; Animals; Anti-Inflammatory Agents, Non-Steroidal | 1999 |
Enhanced anti-inflammatory effects of a nitric oxide-releasing derivative of mesalamine in rats.
Topics: Aminosalicylic Acids; Animals; Anti-Inflammatory Agents, Non-Steroidal; Caspase 1; Cell Adhesion; Ce | 1999 |
Validation of a pharmacokinetic model of colon-specific drug delivery and the therapeutic effects of chitosan capsules containing 5-aminosalicylic acid on 2,4,6-trinitrobenzenesulphonic acid-induced colitis in rats.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Capsules; Chitin; Chitosan; | 1999 |
5-aminosalicyclic acid and olsalazine inhibit tumor growth in a rodent model of colorectal cancer.
Topics: Aminosalicylic Acids; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Cell Division; Co | 2000 |
[The new experimental ulcerative colitis model in rats induced by subserosal injection of acetic acid].
Topics: Acetic Acid; Animals; Anti-Inflammatory Agents; Colitis, Ulcerative; Disease Models, Animal; Inflamm | 2001 |
Anti-inflammatory effects of 5-aminosalicylic acid conjugates with chenodeoxycholic acid and ursodeoxycholic acid on carrageenan-induced colitis in guinea-pigs.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Chenodeoxycholic Acid; Colitis, Ulcer | 2001 |
Effect of aminophenols (5-ASA and 4-ASA) on colonic interleukin-1 generation.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Animals; Colitis; Colon; Disease Models, Animal; Humans; | 1992 |
The effect of therapeutic drugs used in inflammatory bowel disease on the incidence and growth of colonic cancer in the dimethylhydrazine rat model.
Topics: Adenocarcinoma; Aminosalicylic Acids; Animals; Cocarcinogenesis; Colonic Neoplasms; Dimethylhydrazin | 1992 |
Chronic intrajejunal TNBS application in TNBS-sensitized rats: a new model of chronic inflammatory bowel diseases.
Topics: Aminosalicylic Acids; Animals; Disease Models, Animal; Female; Immunization; Inflammatory Bowel Dise | 1992 |
Effect of 5-aminosalicylic acid on myocardial capillary permeability following ischaemia and reperfusion.
Topics: Aminosalicylic Acids; Animals; Capillary Permeability; Coronary Disease; Coronary Vessels; Disease M | 1992 |
Antiinflammatory effects of various drugs on acetic acid induced colitis in the rat.
Topics: Acetates; Acetic Acid; Aminosalicylic Acids; Animals; Anti-Inflammatory Agents; Colitis, Ulcerative; | 1990 |
Arachidonic acid metabolites and their role in inflammatory bowel disease. An update requiring addition of a pathway.
Topics: Aminosalicylic Acids; Arachidonic Acid; Arachidonic Acids; Biological Transport; Bradykinin; Colitis | 1985 |